Japan lodges complaint against Novartis

Share this article:

Japan is filing a criminal complaint against Novartis and its ads for blood pressure medication Diovan. The Japan Times reports that the health ministry's complaint alleges exaggerated advertising, following a September health ministry finding that the company leveraged information from reports that were later discredited for false claims that the drug reduced the risk of cerebral stroke and angina.

The Japan Times says promotional materials for Diovan cited these reports around 700 times. The drug launched in Japan in 2000. Two universities involved in the studies announced in July 2013 that the data had been manipulated.

Novartis has said that it did not know the data was falsified.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.